Michal Vytopil to Cohort Studies
This is a "connection" page, showing publications Michal Vytopil has written about Cohort Studies.
Connection Strength
0.105
-
Arends S, Drenthen J, de Koning L, van den Bergh P, Hadden RDM, Kuwabara S, Reisin RC, Shahrizaila N, Ajroud-Driss S, Antonini G, Attarian S, Balducci C, Bertorini T, Brannagan TH, Cavaletti G, Chao CC, Chavada G, Dillmann KU, Dimachkie MM, Galassi G, Guti?rrez-Guti?rrez G, Harbo T, Islam B, Islam Z, Katzberg H, Kusunoki S, Manganelli F, Miller JAL, Pardo J, Pereon Y, Rajabally YA, Sindrup S, Stettner M, Uncini A, Verhamme C, Vytopil M, Waheed W, Jacobs BC, Cornblath DR. Electrodiagnostic subtyping in Guillain-Barr? syndrome patients in the International Guillain-Barr? Outcome Study. Eur J Neurol. 2024 Sep; 31(9):e16335.
Score: 0.038
-
Al-Hakem H, Doets AY, Stino AM, Zivkovic SA, Andersen H, Willison HJ, Cornblath DR, Gorson KC, Islam Z, Mohammad QD, Sindrup SH, Kusunoki S, Davidson A, Casasnovas C, Bateman K, Miller JAL, van den Berg B, Verboon C, Roodbol J, Leonhard SE, Arends S, Luijten LWG, Benedetti L, Kuwabara S, Van den Bergh P, Monges S, Marfia GA, Shahrizaila N, Galassi G, Pereon Y, B?rmann J, Kuitwaard K, Kleyweg RP, Marchesoni C, Sedano Tous MJ, Querol L, Mart?n-Aguilar L, Wang Y, Nobile-Orazio E, Rinaldi S, Schenone A, Pardo J, Vermeij FH, Waheed W, Lehmann HC, Granit V, Stein B, Cavaletti G, Guti?rrez-Guti?rrez G, Barroso FA, Visser LH, Katzberg HD, Dardiotis E, Attarian S, van der Kooi AJ, Eftimov F, Wirtz PW, Samijn JPA, Gilhuis HJ, Hadden RDM, Holt JKL, Sheikh KA, Kolb N, Karafiath S, Vytopil M, Antonini G, Feasby TE, Faber C, Kramers H, Busby M, Roberts RC, Silvestri NJ, Fazio R, van Dijk GW, Garssen MPJ, Verschuuren J, Harbo T, Jacobs BC. CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barr? Syndrome. Neurology. 2023 06 06; 100(23):e2386-e2397.
Score: 0.035
-
Doets AY, Lingsma HF, Walgaard C, Islam B, Papri N, Davidson A, Yamagishi Y, Kusunoki S, Dimachkie MM, Waheed W, Kolb N, Islam Z, Mohammad QD, Harbo T, Sindrup SH, Chavada G, Willison HJ, Casasnovas C, Bateman K, Miller JAL, van den Berg B, Verboon C, Roodbol J, Leonhard SE, Benedetti L, Kuwabara S, Van den Bergh P, Monges S, Marfia GA, Shahrizaila N, Galassi G, P?r?on Y, B?rmann J, Kuitwaard K, Kleyweg RP, Marchesoni C, Sedano Tous MJ, Querol L, Illa I, Wang Y, Nobile-Orazio E, Rinaldi S, Schenone A, Pardo J, Vermeij FH, Lehmann HC, Granit V, Cavaletti G, Guti?rrez-Guti?rrez G, Barroso FA, Visser LH, Katzberg HD, Dardiotis E, Attarian S, van der Kooi AJ, Eftimov F, Wirtz PW, Samijn JPA, Gilhuis HJ, Hadden RDM, Holt JKL, Sheikh KA, Karafiath S, Vytopil M, Antonini G, Feasby TE, Faber CG, Gijsbers CJ, Busby M, Roberts RC, Silvestri NJ, Fazio R, van Dijk GW, Garssen MPJ, Straathof CSM, Gorson KC, Jacobs BC. Predicting Outcome in Guillain-Barr? Syndrome: International Validation of the Modified Erasmus GBS Outcome Score. Neurology. 2022 02 01; 98(5):e518-e532.
Score: 0.032